Cadila Healthcare (Zydus Cadila) has entered into an exclusive agreement for the technology know-how for varicella vaccine production in the Russian Federation with Pharm Aid, headquartered in Russia. The exclusive agreement was signed at the BIOTECHMED conference in Gelendzhik, Russia.
The agreement aims to bring in a continuous supply of vaccines which could be included in the critical childhood immunization programme. The demand is estimated at 3 million doses per annum in the Russian Federation alone.
Through this agreement, Zydus gained access to the public and private market segments in the Russian Federation, Belarus, Uzbekistan, Kazakhstan, Armenia and Kyrgyzstan. With an absence of assured supply of indigenously manufactured varicella vaccine, this vaccine does not feature currently in the National Immunisation Programme.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
